» Authors » Eliseo Pastor-Villalba

Eliseo Pastor-Villalba

Explore the profile of Eliseo Pastor-Villalba including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 55
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez-Lacort M, Munoz-Quiles C, Mira-Iglesias A, Lopez-Labrador F, Garces-Sanchez M, Escribano-Lopez B, et al.
Pediatrics . 2024 Oct; 155(1. PMID: 39363387
Objectives: This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTIs) in a large primary care network in Spain,...
2.
Juaneda J, Estrella-Porter P, Blanco-Calvo C, Orrico-Sanchez A, Antonio Lluch-Rodrigo J, Pastor-Villalba E
Vaccines (Basel) . 2024 Jun; 12(6). PMID: 38932352
Public funding of vaccines may enhance vaccination rates, co-administration, and timeliness. The impacts of including the serogroup B meningococcus vaccine (MenB) into the national immunisation schedule on vaccination rates, co-administration...
3.
Estrella-Porter P, Blanco-Calvo C, Lameiras-Azevedo A, Juaneda J, Fernandez-Martinez S, Gomez-Pajares F, et al.
Vaccine . 2024 Jun; 42(22):126030. PMID: 38834430
Respiratory syncytial virus (RSV) represents a high burden of disease in children and the primary cause of hospitalization, especially in children under 1 year old. In the Valencian Community (Spain),...
4.
Lopez-Lacort M, Munoz-Quiles C, Mira-Iglesias A, Lopez-Labrador F, Mengual-Chulia B, Fernandez-Garcia C, et al.
Euro Surveill . 2024 Feb; 29(6). PMID: 38333937
The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023-Jan...
5.
Carreras J, Lluch J, Taboada J, Pastor-Villalba E, Nartallo-Penas V, Diez-Domingo J
Enferm Infecc Microbiol Clin (Engl Ed) . 2022 Dec; 41(7):420-422. PMID: 36456431
Influenza vaccination in pregnant women shows a clear benefit/risk ratio. Influenza vaccines are currently being developed using new platforms. It is essential to analyse the safety of these new vaccines...
6.
Egoavil C, Tuells J, Carreras J, Montagud E, Pastor-Villalba E, Caballero P, et al.
Vaccines (Basel) . 2020 Mar; 8(1). PMID: 32131535
Vaccine safety surveillance is essential in vaccination programs. We accomplished a descriptive study of surveillance AEFI-reporting rate in human papillomavirus (HPV) vaccine administered in the Valencian Community, Spain. Data were...
7.
Boone A, Beso-Delgado M, Alguacil-Ramos A, Pastor-Villalba E, Portero-Alonso A
An Pediatr (Barc) . 2016 May; 85(6):320-321. PMID: 27131729
No abstract available.
8.
Martin-Ivorra R, Alguacil-Ramos A, Lluch-Rodrigo J, Pastor-Villalba E, Portero-Alonso A
Rev Esp Salud Publica . 2015 Nov; 89(4):419-26. PMID: 26580797
Eliminating measles and rubella and preventing congenital rubella infection plan of WHO highlighted the need to assess vaccination coverage and develop strategies to improve it and eliminate pockets of low...
9.
Diez-Domingo J, Ridao-Lopez M, Gutierrez-Gimeno M, Puig-Barbera J, Lluch-Rodrigo J, Pastor-Villalba E
Vaccine . 2011 Oct; 29(52):9640-8. PMID: 22027484
Background: Heptavalent pneumococcal conjugate vaccine (PCV-7) was licensed to provide immunity against pneumococcal disease caused by seven serotypes of S. pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV-13) includes 6 additional serotypes...
10.
Palacio J, Leon-Artozqui M, Pastor-Villalba E, Carrera-Martin F, Garcia-Belenguer S
J Feline Med Surg . 2006 Dec; 9(3):188-95. PMID: 17188013
Feline aggression towards people has a smaller incidence than canine aggression, but also represents an important public health problem. The aim of this work was to analyse feline aggression reported...